US-China firm Ablaze Pharma nets $75m co-led by Vivo Capital

Photo: Pixabay

Ablaze Pharmaceuticals, a clinical-stage pharmaceutical company with offices in Shanghai and San Diego, has garnered $75 million in its Series A round funding, the firm announced on Monday. 

The fresh round was jointly led by AdvanTech Capital and Vivo Capital, a Palo Alto-based investment firm that backs the US and China healthcare market. 

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter